Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM33 | Q9BZ11 | 4/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680361 | 1.00 | ADAM33 (0.56) | ADAM33MMP3MAPTALDH1A1POLB | |
| SCHEMBL2681241 | 0.88 | ADAM33 (0.54) | ADAM33MMP3ALDH1A1TP53 | |
| SCHEMBL2681236 | 0.88 | ADAM33 (0.54) | ADAM33MMP3ALDH1A1TP53 | |
| SCHEMBL997766 | 0.87 | ADAM33 (0.59) | ADAM33MMP3MAPTALDH1A1POLB | |
| SCHEMBL997767 | 0.87 | ADAM33 (0.59) | ADAM33MMP3MAPTALDH1A1POLB | |
| SCHEMBL27853836 | 0.85 | ADAM17 (0.56) | ADAM33MMP3ALDH1A1 | |
| SCHEMBL995019 | 0.85 | ADAM33 (0.45) | ADAM33MMP3ALDH1A1 | |
| SCHEMBL996102 | 0.85 | ADAM33 (0.45) | ADAM33MMP3ALDH1A1 | |
| SCHEMBL2680581 | 0.85 | ADAM33 (0.79) | ADAM33MMP3 | |
| SCHEMBL2680577 | 0.85 | ADAM33 (0.79) | ADAM33MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772478-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-07-08 | — | — | US | disclosed |
| US-20120116072-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPEMENT (FR) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116072-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | TYR, ARSA, STS | ADAM33 3905/4885MMP3 3872/4885MAPT 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.